Secondarily, in a distinct cohort of patients with advanced NSCLC, we used transcriptomic analysis to demonstrate the correlation of tumorous IL-6 expression with NSCLC treatment response and survival with single-agent ICI. This evidence concerns the gene IL6 and non-small cell lung carcinoma.